AR002024A1 - Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas. - Google Patents

Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.

Info

Publication number
AR002024A1
AR002024A1 ARP960101201A AR10120196A AR002024A1 AR 002024 A1 AR002024 A1 AR 002024A1 AR P960101201 A ARP960101201 A AR P960101201A AR 10120196 A AR10120196 A AR 10120196A AR 002024 A1 AR002024 A1 AR 002024A1
Authority
AR
Argentina
Prior art keywords
xaa
leu
ser
val
thr
Prior art date
Application number
ARP960101201A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR002024A1 publication Critical patent/AR002024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se describen proteínas anti-obesidad, que regulan el tejido adiposo cuando se administran al paciente, con lo cual es posible solucionar y/o prevenir losriesgos colaterales, debido a los estados de diabetes tipo II, cáncer o enfermedades cardiovasculares, asociados con la obesidad. Se trata de proteínasque tienen la secuencia (SEQ ID NO: 1) Val Pro Ile Xaa Lys Val Xaa Asp Asp Thr Lys Thr Leu Ile Lys ThrIle Val Thr Arg Ile Xaa Asp Ile Ser His XaaXaa Ser Val Ser Ser Lys Xaa Lys Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro IleLeu Thr Leu Ser Lys Xaa Asp Xaa Thr Leu Ala Val Tyr Xaa Xaa Ile Leu Thr Ser Xaa Pro Ser Arg Xaa Val Ile Xaa Ile Ser Xaa LeuGluc Xaa LeuArg Asp Leu Leu His Val Leu Ala Phe Ser Lys Ser Cys His Lue Pro Xaa Ala Ser Gly Leu Glu Thr Leu Xaa Ser Leu Gly GlyVal Leu Glu Ala Ser Gly Tyr Ser Thr Val Val Ala Leu Ser Arg Leu Xaa Gly Ser Leu Asp Xaa Leu Xaa XaaLeu Asp Leu Ser Pro Gly CysLas referencias numéricas están ilustradas en la descripción y 1era. reinvidicación.
ARP960101201A 1995-01-31 1996-01-30 Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas. AR002024A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38104895A 1995-01-31 1995-01-31
US38363895A 1995-02-06 1995-02-06

Publications (1)

Publication Number Publication Date
AR002024A1 true AR002024A1 (es) 1998-01-07

Family

ID=27009220

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101201A AR002024A1 (es) 1995-01-31 1996-01-30 Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.

Country Status (10)

Country Link
EP (2) EP0725079A1 (es)
JP (1) JPH10513450A (es)
AR (1) AR002024A1 (es)
AU (1) AU4766196A (es)
CA (1) CA2211664A1 (es)
CO (1) CO4480036A1 (es)
PE (1) PE15297A1 (es)
TR (1) TR199600084A2 (es)
WO (2) WO1996023515A1 (es)
YU (1) YU5396A (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357096A (ja) * 1986-08-29 1988-03-11 工業技術院長 紐体切断装置
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
EP0736599A3 (en) * 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
EP0741187A2 (en) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
YU29596A (sh) * 1995-05-19 1998-07-10 Eli Lilly And Company Genski proizvodi koji regulišu gojaznost
WO1996037517A1 (en) * 1995-05-26 1996-11-28 Eli Lilly And Company Rhesus ob protein and dna
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
EP0764722A2 (en) * 1995-09-19 1997-03-26 Eli Lilly And Company DNA encoding primate leptins as medicinal proteins
US6225446B1 (en) 1995-12-06 2001-05-01 Schering Corporation Mutational variants of mammalian proteins
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
EP0786256A3 (en) * 1996-01-19 1999-08-18 Eli Lilly And Company Obesity protein formulations
JP2000505078A (ja) * 1996-01-19 2000-04-25 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
EP0784982A3 (en) * 1996-01-19 1999-08-18 Eli Lilly And Company Obesity protein formulations
EP0877627A1 (en) * 1996-01-25 1998-11-18 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
AU1838797A (en) * 1996-02-06 1997-08-28 Eli Lilly And Company Obesity protein compounds and formulations thereof
HUP0000280A3 (en) * 1996-03-01 2002-09-30 Amgen Inc Thousand Oaks Canine ob protein compositions and methods
JP2000509018A (ja) * 1996-03-26 2000-07-18 イーライ・リリー・アンド・カンパニー 肥満タンパク質製剤
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
AU4160597A (en) * 1996-08-23 1998-03-06 Eli Lilly And Company Protein formulations
AU4582597A (en) * 1996-10-11 1998-05-11 Eli Lilly And Company Therapeutic proteins
WO1998024896A2 (en) * 1996-12-06 1998-06-11 F. Hoffmann-La Roche Ag Muteins of obese protein
AU5802898A (en) * 1996-12-20 1998-07-17 Eli Lilly And Company Anti-obesity proteins
EP0973535A1 (en) * 1996-12-20 2000-01-26 Eli Lilly And Company Protein crystals, their preparation and use
CA2217698A1 (en) * 1996-12-20 1998-06-20 Eli Lilly And Company Anti-obesity proteins
WO1998031390A1 (en) * 1997-01-17 1998-07-23 Eli Lilly And Company Obesity protein formulations
US5965521A (en) * 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
EP0991420A1 (en) * 1997-02-25 2000-04-12 Eli Lilly And Company Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
KR101397913B1 (ko) 2005-05-30 2014-05-26 엠에스디 가부시키가이샤 신규 피페리딘 유도체
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
KR101318127B1 (ko) 2005-11-10 2013-10-16 엠에스디 가부시키가이샤 아자 치환된 스피로 유도체
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
CN101981025A (zh) 2008-03-28 2011-02-23 万有制药株式会社 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
WO2009143380A2 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2352510A4 (en) 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA032917B1 (ru) 2010-09-28 2019-08-30 Амилин Фармасьютикалс, Ллк Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
PT2729160T (pt) 2011-07-08 2019-07-08 Aegerion Pharmaceuticals Inc Polipéptidos modificados com uma maior duração da ação e uma imunogenicidade reduzida
DE102012106607B4 (de) 2012-07-20 2024-04-04 Heliatek Gmbh Verfahren zur Versiegelung von Modulen mit optoelektronischen Bauelementen
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
SI3509624T1 (sl) 2016-09-12 2023-12-29 Amryt Pharmaceuticals, Inc., Postopki detektiranja nevtralizirajočih protiteles proti leptinu
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
AU2019385644A1 (en) 2018-11-20 2021-06-03 Tes Pharma S.R.L. Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase
CN115362165A (zh) * 2020-03-11 2022-11-18 安尼根有限公司 包含新型化合物的用于抗糖尿病和抗肥胖的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
FI931701A (fi) * 1992-04-17 1993-10-18 Sankyo Co Derivat av faktor som inhiberar fettbildning, framstaellning och anvaendning
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
TR199600084A2 (tr) 1996-08-21
JPH10513450A (ja) 1998-12-22
PE15297A1 (es) 1997-05-22
WO1996023517A1 (en) 1996-08-08
CO4480036A1 (es) 1997-07-09
AU4766196A (en) 1996-08-21
WO1996023515A1 (en) 1996-08-08
CA2211664A1 (en) 1996-08-08
EP0725078A1 (en) 1996-08-07
EP0725079A1 (en) 1996-08-07
YU5396A (sh) 1998-08-14

Similar Documents

Publication Publication Date Title
AR002024A1 (es) Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
BR9908749A (pt) Composições e formulações de peptìdios e uso das mesmas
NO20053027L (no) Gastrinpreparater og formuleringer, og fremgangsmater for anvendelse og fremstilling.
AU4371799A (en) Lysine containing peptides for treatment of heart disease
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
WO1997015598A1 (en) Novel peptide
KR950702579A (ko) 트롬빈 억제제(thrombin inhibitors)
CA2266346A1 (en) Use of proteins as agents against autoimmune diseases
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides
NO975565L (no) Benstimulerende faktor
Ferreira et al. Structure and effects of a kinin potentiating fraction F (AppF) isolated from Agkistrodon piscivorus piscivorus venom
NO991653L (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
AU2002365974A1 (en) Alpha-fetoprotein peptides and uses thereof
BR0007816A (pt) Fator de estimulação óssea
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
IL115825A0 (en) Therapeutic protein
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
WO2001021653A3 (en) Ovarian tumor antigen and methods of use therefor
US4840785A (en) Mammal intestinal hormone precursor and its use
TH34900A (th) โปรตีนยับยั้งความอ้วน
Bondesson et al. Dual effects of vasoactive intestinal peptide on the migration of leucocytes
Ishizaka et al. Analysis of the immunoactivator sites of parotid protein isolated from bovine parotid glands
TH23897B (th) โปรตีนต้านความอ้วน